W e thank Jama et al 1 for their commentary on our article published in Nature Communications this year entitled Gut microbiota associations with common diseases and prescription medications in a populationbased cohort. 2 In our article, we set out to study, in 1 population, common disease associations with gut microbiota composition together in the same dataset. The aim was to compare the relative level and overlap of microbiome associations between multiple diseases, rather than provide a definitive reference of associations for each disease considered. We think this endeavor is important because diseases cluster together, and individuals with 1 disease frequently suffer from comorbidities and general frailty, 3, 4 which itself has been associated with changes in the gut microbiome. 5 A key finding was that a series of nonspecific of microbiota associations are present across many different diseases.
Our results showed that some diseases and disorders did seem to have a disproportionate number of associations with the gut microbiome. Jama et al 1 is correct to state that, in our analyses, hypertension was not among them, despite the large numbers of individuals reporting the disorder and thus our power to detect effects. Although this is indicative that hypertension may have relatively less association with gut microbiome composition than other diseases, we agree that this should not be misconstrued as entirely negative findings for hypertension in association with the gut microbiota.
The consideration of multiple diseases inherently limited our power to detect significant associations with individual conditions. This is also the reason that we adopted a data reduction strategy for the microbiota. The microbiota tested are marker features picked to represent the correlation structure in the wider microbiome data. Thus, hypertension may well have additional associations among the microbiome features that were not considered. Similarly, we only considered taxonomic measures; there may be functional aspects of the microbiome associated with hypertension that would be better explored using platforms such as metabolomics and metatranscriptomics. The null findings for hypertension should, therefore, not be interpreted as negative except in comparison relative to the other common diseases ascertained in a similar way.
Our study used self-reported phenotypic data for both medication use and for all diseases. As suggested by Jama et al, 1 this may lead to less accurate quantitation of hypertension cases. However, self-reported condition was used throughout to provide an unbiased quantitation across all phenotypes, as many are less readily diagnosed than hypertension. The TwinsUK cohort, a long-running population-based cohort of British twins, is also enriched for health-motivated individuals who have had their blood pressure measured at multiple visits and this information fed back to them and their General Practitioners. It is, therefore, unlikely, in our view, that those denying hypertension are, in fact, hypertensive. Furthermore, the proportion in our largely female study who report hypertension (27.6%) is in keeping with data from the UK female population (26%; Health Survey for England 2015). 6 Jama et al 1 also suggest that the confounding between comorbidities and drugs may account for the lack of associations between the gut microbiome and hypertension. Indeed, in our dataset, hypertension status is highly correlated with a range of diseases, including hypercholesterolemia, ischaemic heart disease, atrial fibrillation, diverticular disease, and cataracts. However, the modeling approach used would identify similar associations with 2 sufficiently highly correlated diseases as no adjustment for comorbidities was performed in individual disease-microbiota models. Furthermore, as stated by Jama et al 1 , we also observed relatively few associations with hypertensive drugs. A more likely reason for the relatively low number of associations observed with hypertension is the influence of age and body mass index, which were adjusted for in our analyses. Both influence the gut microbiota 7, 8 and are highly correlated with hypertension. However, it will be difficult to delineate these, and dietary, effects from hypertension without further carefully designed studies, such as advocated by Jama et al 1 
.
However, it cannot also be assumed that there will be associations specific to hypertension independent of other effects.
Lastly, Jama et al 1 notes that we observed few associations between the gut microbiota and hypertension. Indeed, we did not observe the same associations with ACE (angiotensin-converting enzyme) inhibitor and β-blockers as in
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Response to: Microbiome and Hypertension 1189 the referenced Zhernakova et al 9 study. However, it should be noted these explained >1% of variance in the β-diversity measure in the study and had a very low correlation with alpha diversity measures. It is, therefore, not unexpected that we do not see that same effect when considering numerous other medications, in an older population, with higher levels of comorbidity and multidrug use. We disagree with Jama et al 1 on the assertion that it is reasonable to assume that antihypertensive drugs get rid of opportunistic and adverse bacterial species and that we should assume drugs to lower blood pressure to improve gut biosis. Drug use is an inherent marker of morbidity. As stated in our study, we did not consider drug and disease effects independently, drug associations may simply reflect disease effects. It is also impossible to prove/discount positive or adverse effects of medications on microbiome without targeted mechanistic studies. Understanding the consequences of drug-microbiome interactions on the host is also nontrivial. However, our study is certainly insufficient to discount that gut microbes may modulate bioavailability, metabolism, and effect of hypertensive medications. We look forward to further targeted studies that explore these effects further.
Conclusions
In our study, hypertension did not stand out as a disorder that is associated with specific alterations in the microbiota. However, our study looked at marker traits of microbiome composition, and, therefore, further studies may be able to detect significant specific microbiota or, in particular, microbial functions which may be important in hypertension. More studies into microbial-pharmacology are recommended and may yield insights into variable response to antihypertensive agents. Overall, we agree that more disease-specific studies are warranted not only for hypertension, but the other common disorders considered in our previous study. We would urge that human studies of any disease should account for correlated diseases, medications, and other host factors, such as general health to avoid being overwhelmed by nonspecific effects. 
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